natgillin/translations-raw huggingface dataset:
The beverage production device according to claim 10, wherein in order to evacuate the at least two thermoblocks, valve means are provided to selectively vent air through the hot water outlet and into the thermoblocks for emptying the thermoblocks. A brewing-type beverage production device, comprising: at least one water reservoir, 
Naprava za proizvodnju napitaka prema patentnom zahtjevu 10 ili 11, kod koje su, kako bi sc ispraznilo najmanje dva termobloka (3, 4), ugrađeni ventili (19, 20) za selektivno upuhivanje zraka kroz izlaz za vruću vodu (14), te u termoblokove (3, 4) radi pražnjenja termoblokova.
permanently magnetizing the engraved body of step b), preferably in a direction substantially perpendicular to the indicia-carrying surface. 
€) permanentno magnetiziranje graviranog tijela iz koraka b) u smjeru koji je u znatnoj mjeri okomit na površinu koja nosi oznaku.
Monoclonal antibodies include chimeric antibodies, human antibodies and humanized antibodies and may occur naturally or be recombinantly produced. 
(a) antitijelo je odabrano od humanog antitijela, humaniziranog antitijela, bispecifičnog antitijela i kimernog antitijela;
Use according to claim 19 wherein the antidepressant medication is selected from the group consisting of mirtazapine, amitryptiline and paroxetine. 
Upotreba prema zahtjevu 20, gdje se antipsihotični agens bira iz skupine koja se sastoji iz mirtazapina, amitriptilina i paroksetina.
15: embodiment of the system of the invention 
Broj objave europskog patenta:
Patent Document 1: European Patent Publication No. 
Datum objave europske prijave patenta:
The mercurial preservative-free immunogenic composition for use according to claim 1, wherein the immunogenic composition has a dose volume of about 0.5 ml or of about 0.25 ml. 
Imunogeni pripravak koji ne sadrži konzervans na bazi žive, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što imunogeni pripravak ima volumen doze od otprilike 0,5 ml ili od otprilike 0,25 ml.
The antibody or fragment thereof for use according to Claim 14, wherein said anti-neoplastic agent is selected from the group consisting of docetaxel, paclitaxel, Herceptin® and doxorubicin. 
Protutijelo, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačeno time što se navedeno antineoplastično sredstvo bira iz skupine koju čine docetaksel, paklitaksel, Herceptin® i doksorubicin.
It is preferred that the calcium carbonate containing mineral is selected from the group consisting of marble, chalk, limestone, calcite, dolomite and precipitated calcium carbonate (PCC), and mixtures thereof. 
Postupak prema zahtjevu 1, naznačen time da se navedeni kalcijev karbonat koji sadrži mineral bira iz skupine koju čine mramor, kreda, vapnenac, kalcit, dolomit, istaloženi kalcijev karbonat (PCC), te od njihovih smjesa.
A computer system for executing a store instruction for storing data in an adapter, said computer system comprising: 
Računalni sustav za izvršavanje upute za pohranu podataka u adapter, taj računalni sustav obuhvaća:
Carpet (1) as claimed in claim 2, wherein at least half the fibres of the high, piles (2) have a weight less than 5 dTex. 
Tepih (1) prema zahtjevu 2, naznačen time, da barem polovica vlakana visokog flora (2) ima težinu manju od 5 dtex.
The compound of claim 1, wherein R1 is and R2 is a substituted or unsubstituted phenyl. 
Co 9 ž i R? je supstituiran ili nesupstituiran fenil.
The anti-CTLA-4 antibody and 4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-B-D-glucopyranoside or a pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to any one of Claims 1 to 8, wherein said cancer treatment further comprises an anti-proliferative cytotoxic agent either alone or in combination with radiation therapy. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-B-D-glukopiranazid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 8, gdje navedeno liječenje raka dalje sadrži anti-proliferativni citotoksični agens ili sam ili u kombinaciji sa radioterapijom.
The method according to the invention is suited for the production of a secreted heterologous immunoglobulin in large scale, i.e. industrially. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 17 1 19 do 21, naznačen time, da je postupak pogodan za proizvodnju izlučenog heterolognog imunoglobulina u velikom opsegu.
According to the present invention there is provided a crystalline form, mono-HCl salt Form A1 which has an X-ray powder diffraction pattern with specific peaks at 2-theta=12.3, 13.9, 9.3, 23.3, 18.7, 16.0, 24.6, 26.8, 28.0° wherein said values may be plus or minus 0.2° 2-theta. 
Mono-HCI so spoja formule (I), prema patentnom zahtjevu 3, u kristalnom obliku koji ima obrazac rentgenske difrakcije praha sa specifičnim pikovima na 2-teta = 12.3, 13.9, 9.3, 23.3, 18.7, 16.0, 24.6, 26.8, 28.0" sa greškom mjerenja za svaki difrakcijski kut koji je plus ili minus 0.2".
The system of claim 2 wherein the first stimulation component is configured to provide direct current electrical stimulation. 
Sustav sukladno zahtjevu 1 pri čemu je prva stimulacijska komponenta konfigurirana na način da omogućava:
the wt human extracellular domain of FAPa (SEQ ID NO: 448) on the cell surface; 
(i) ljudsku izvanstaničnu domenu FAPa divljeg tipa sa SEQ ID:448 na površini stanice;
a float integral with a position sensor configured to measure a level of water in a tank; and 
• plovak (7A-6) kruto povezan sa senzorom položaja (7A-5) za mjerenje razine vode u spremniku;
an open eutectic carbide network with eutectic carbides of less than (<) 5 % per volume; 
otvorenu eutektičnu karbidnu mrežu s eutektičnim karbidom manjim od (
This reaction is preferably performed in a dipolar aprotic solvent such as dimethyl formamide (DMF) or dimethylacetamide (DMAc). 
Reakcija se poželjno provodi u dipolarnom aprotičnom otapalu kao što je dimetil formamid (DMF) ili dimetilacetamid (DMAc).
The method of claim 1, wherein the C1 inhibitor is administered at least one hour after the start of reperfusion. 
Upotreba u skladu s patentnim zahtjevom 1, naznačena time što inhibitor C1 se primijenjuje između najmanje 10 minuta i 24 sata nakon trajanja ishemije i/ili početka reperfuzije.
receive a notification from the medium access controller that transmission of the error control message has begun; and 
prihvaćanje obavijesti da je započeo prijenos poruke nadzora nad pogreškom.
OH, oxo, -CN, halogen, -methyl, -ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, -O-C1-6-alkyl, -C1-6-haloalkyl, three- to seven-membered cycloalkyl, Het, Hetaryl, -CO-N(CH3)2, -CO-NHCH3, -CO-NH2, -(C1-3-alkylene)-O-(C1-3-alkyl), -O- Het, which is optionally further substituted by one, two or three substituents X, whereby each X is selected from the group consisting of halogen, oxo, -C1-4-alkyl, -O-C1-4-alkyl, -C1-4-haloalkyl, -O-(C1-4-alkylene)- Het, Het, -NH2, whereby substituent X is optionally further substituted by one, two or three substituents of a group selected from oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl, and the pharmaceutically acceptable salts of the aforementioned compounds. 
CO-N(CH3)2, -CO-NHCH3, -CO-NH2, -(C1-3-alkilen)-O-(C1-3-alkil), -O-Het, koji je opcionalno dalje supstituiran s jednim, dva ili tri supstituenta X, pri čemu je svaki X odabran iz skupine koja se sastoji od sljedećih: halogen, okso, -C1-4-alkil, -O-C1-4-alkil, -C1-4-haloalkil, -O-(C1-4-alkilen)-Het, Het, -NH2, pri čemu je supstituent X opcionalno dalje supstituiran s jednim, dva ili tri supstituenta iz skupine odabrane od okso, metila, etila, n-propila, izopropila, n-butila, izobutila i tert-butila, i farmaceutski prihvatljive soli od gore spomenutih spojeva.
Such housing does not allow visual inspection of the parts of the assembly or of the content of the bottle. 
Takovo kućište ne dopušta očnu kontrolu dijelova sklopa ili sadržaja boce.
A pharmaceutical kit for the in situ formation of a biodegradable implant in a body comprising the composition of any one of claims 1-14, wherein the drug and the biocompatible polymer are contained in a first container, and the water-miscible solvent is contained in a second, separate container. 
Farmaceutski komplet za in situ formiranje biorazgradivog implantata u tijelu koji sadržava sastav iz bilo kojeg od prethodnih zahtjeva 1 do 12, pri čemu se lijek i biokompatibilni polimer nalaze u prvom spremniku, a otapalo mješljivo s vodom nalazi se u drugom, zasebnom spremniku.
A pharmaceutical composition, comprising a peptide consisting of the amino acid sequence of SEQ ID NO 2, and a peptide consisting of the amino acid sequence of SEQ ID NO 3, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav koji sadrži peptid sa SEQ ID NO 1 i peptid sa SEQ ID NO 2, te farmaceutski prihvatljiv nositelj.
Preferably, the Borrelia organism is selected from the group comprising B. burgdorferi, particularly B. burgdorferi s.s., B. garinii, B. afzelii, B. andersoni, B. bavariensis, B. bissettii, B. valaisiana, B. lusitaniae, B. spielmanii, B. japonica, B. tanukii, B. turdi or B. sinica, preferably B. burgdorferi s.s., B. afzelii or B. garinii. 
Polipeptid sukladno bilo kojem patentnom od zahtjeva 1 do 4, nukleinska kiselina prema zahtjevu 5 ili farmaceutski pripravak prema bilo kojem od zahtjeva 8 do 13 za uporabu u postupku liječenja ili prevencije infekcije Borrelia, osobito B. burgdorferi s.s., B. garinii, B. afzelii, B. andersoni, B. bavariensis, B. bisseltii, B. valaisiana, B. lusitaniae, B. spielmanii, B. japonica, B. tanukii, B. turdi ili B. sinica infekcije, poželjno B. burgdorferi s.s., B. afzelii ili B. garinii infekcije.
wherein Ra and Rb are independently a hydrogen or an organic residue selected from the group consisting of substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, hydroxy, lower alkoxy, carboxy or alcoxycarbonyl; or 
Formula (I) gdje su R* i R" nezavisno vodik ili organski ostatak izabran iz grupe koju čine supstituirani ili nesupstituirani niži alkil, supstituirani ili nesupstituirani niži alkenil, supstituirani ili nesupstituirani niži alkinil, hidroksi, niži alkoksi, karboksi ili alkoksikarbonil; ili
A system according to the claim 1, in which 
Sustav prema zahtjevu 1, gdje
The compound of Claim 15, where R3 and R5 are hydrogen, and: 
Spoj u skladu s patentnim zahtjevom 15, naznačen time, da su R3 i R5 vodik, i:
According to the invention, preferably, the beam-like block of wood has a relative wood humidity of > 30 % prior to the cutting. 
Poželjno je da u skladu s ovim izumom blok od drva koji ima oblik grede ima relativnu vlažnost drva od > 30 % prije rezanja.
A pharmaceutical composition comprising a compound of claim 27, and a pharmaceutically acceptable excipient. 
Farmaceutski sastav koji sadrži spoj prema bilo kojem od zahtjeva 1-19, i farmaceutski prihvatljivu pomoćnu tvar.
If the rate needs to be changed because of a change in tons/hour being harvested, or for a difference crop or target product, a variable speed pump allows the same. Compressor 50 
Ako je potrebno da se brzine mijenjaju zbog promjene količine požnjevenih usjeva u t/h, ili zbog promjene usjeva ili ciljnog proizvoda, to će omogućiti pumpa promjenjive brzine.
A method for the preparation of a compound of general formula (VIII): where R1 is hydrogen, alkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, aryl or pyridyl; the term alkyl means a straight or branched hydrocarbon chain containing from 1 to 18 carbon atoms; the term halogen means fluorine, chlorine, bromine or iodine; the term cycloalkyl means an alicyclic saturated group with 3 to 6 carbon atoms; and the term aryl means an unsubstituted phenyl group or phenyl substituted by alkoxy, halogen or nitro group, said method comprising reacting (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (II) by a method according to claim 1, or according to any one of claims 3 to 11, when dependent on claim 1. 
N S 0% *NH, (VITI) gdje je R, vodik, alkil, halogenalkil, aralkil, cikloalkil, cikloalkilaril, aril ili piridil; izraz alkil znači linearni ili razgranati ugljikovodični lanac koji sadrži 1 - 18 atoma ugljika; izraz halogen znači fluor, klor, brom ili jod; izraz cikloalkil znači alicikličku zasićenu skupinu sa 3 do 6 atoma ugljika; te izraz aril znači nesupstituiranu fenil skupinu ili fenil supstituiran alkoksi, halogen ili nitro grupom, pri čemu spomenuti postupak sadrži reagiranje (R)-(-)-10,11- dihidro-10-hidroksi-5H-dibenz/b,fazepin-5-karboksamida (II) postupkom prema patentnom zahtjevu 1, ili prema bilo kojem od zahtjeva 3 do 12, kad se oni pozivaju na patentni zahtjev 1.
The soft chewable veterinary composition of paragraph 4, wherein the one or more fillers is soy protein fines, corn starch, or a mixture thereof. 
Per -NH Gi Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 1, naznačen time, da farmaceutski prihvatljiv nosač obuhvaća jedno ili više punila.
Selection of suitable water-in-oil emulsifiers is well known in the formulation art. 
Odabir prikladnih voda-u-ulju emulgatora je dobro poznat u struci izrade pripravaka.
In an embodiment, the present invention provides a method for enhancing high availability in a secure telecommunications network. 
PATENTNI ZAHTJEVI Metoda za poboljšanje visoke dostupnosti u sigurnoj telekomunikacijskoj mreži (10), telekomunikacijska mreža
The tablet as in item 36, wherein said tablet has a hardness value within the range of about 28-39 SCUs. 
Tableta kao što je zahtijevano u patentnom zahtjevu 9, pri čemu navedena tableta ima vrijednost čvrstine unutar opsega od oko 28-39 SCUs.
Preferably said inhaler (5) is a plastic material which said strap and said body moulded as a unit. 
Poželjno, navedeni inhalator (5) načinjen je od plastičnog materijala pri čemu su navedena vrpca i navedeno tijelo izliveni kao jedan dio.
is -O- and A2 is -CH2-, wherein a compound of formula VII is reacted with a compound of formula VIII to generate a compound of formula IX in which formulae 
je -O-; i je -CH2-, naznačen time što spoj formule VII [image] reagira sa spojem formule VIII [image] kako bi se dobilo spoj formule IX [image], gdje formule
reacting a compound of Formula LXVII 
Formula IXa čime se dobiva spoj Formule LXIII:
Figs 53a-c show an instrument for creating an invagiation of the wall of the stomach that can either be placed on the outside of the wall of the stomach or on the inside of the wall of the stomach depending if the reflux treatment device is place on the inside or the outside of the wall. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je uređaj prilagođen da bude u najmanju ruku djelomično invaginiran u stijenku želuca međuželučanim kopčama, s vanjske strane stijenke želuca.
The composition for use according to claim 13, wherein crenolanib or a salt thereof is provided as a single agent in treatment of subjects with the acute myeloid leukemia (AML) that is either refractory to, or has relapsed after prior treatment with a chemotherapeutic agent. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 13, pri čemu se crenolanib ili njegova sol osigurava kao jedini agens u liječenju subjekata s akutnom mijeloičnom leukemijom (AML) koja je ili refraktorna ili je relapsirala nakon prethodnog liječenja kemoterapijskim agensom.
Apparatus for carrying out a process according to claim 1, comprising: 
Uređaj (10) za provođenje postupka prema zahtjevu 1, koji sadrži:
m and n can be independently from 1 to 3; 
m i n mogu biti neovisno od 1 do 3;
Trichloroethylene (5.71) was added and stirring was continued over night at room temperature. 
Dodan je trikloroetilen (5,7 1) i miješanje je nastavljeno preko noći na sobnoj temperaturi.
The DSC equipment contained a measuring cell based on heat flux principle with a ceramic sensor and a furnace supply which can be used in the temperature range 0 to 300°C. The heating rate was at least in the range of 1-20 °C/min. 
DSC oprema sadržavala je stanicu za mjerenje baziranu na principu protoka vrućine s keramičkim senzorom i dodatkom za zagrijavanje u temperaturnom rasponu 0 do 300 "C. Stopa zagrijavanja bila je najmanje u rasponu od 1-20 *C/min.
Table 7 Samples Date of manufacturing 
Datum podnošenja zahtjeva u HA:
In one embodiment, 3-dosage units are administered weekly for a period of 3 weeks, followed by one week of no administration of a dosage unit or administration of a placebo. That is to say that the kit is intended for a treatment period of 4 weeks and the kit comprises 1-3 dosage units. 
Komplet prema zahtjevu 5, naznačen time da je komplet namijenjen za razdoblje liječenja od 4 tjedna i komplet sadrži 3 jedinične doze koje se daju tjedno tijekom perioda od 3 tjedna, nakon čega slijedi tjedan dana bez davanja jedinica doziranja ili davanje placeba.
A compound for use as modulator in the treatment of cystic fibrosis represented by the following structure: its tautomers, or its pharmaceutically acceptable salts thereof or complexes thereof 
Tvar za uporabu u skladu s patentnim zahtjevom 1 ili 2, navedena tvar je predstavljena sljedećim strukturama:
When the level of pre-load is high, stretching of the wireline commences at lower wireline tension than when the pre-load is less (giving rise to a less stiff system overall). 
Kada je razina prethodnog opterećenja suviše velika, zatezanje žičane veze počinje pri manjem naponu žičane veze u usporedbi kada je predopterećenje manje (dajući u općem slučaju porast manje krutom sustavu).
The extended release tablet formulation of claim 4, wherein the matrix comprises about: (a) pramipexole or a salt thereof 
Formulacija tablete produljenog oslobađanja u skladu sa zahtjevom 4, naznačena time, da matrica sadrži oko: (a) pramipeksol ili njegovu sol 0.05 do 5 mas. %
A process as claimed in Claim 5, wherein the bromination is performed in the presence of 5,5-dibromo barbituric acid. 
Postupak prema zahtjevu 5, naznačen time da se bromiranje provodi u prisutnosti 5,5-dibromo barbituratne kiseline.
Process according to any one of the preceding claims, CHARACTERIZED in that the esters of fatty acids are distilled at a pressure lower than 0.1 mbar and a temperature lower than 150°C. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se esteri masnih kiselina destiliraju pod tlakom ispod 0,1 mbar (10 Pa) 1 na temperaturi ispod 150%C.
These pharmaceutical preparations are a further object of the invention. 
Ove farmaceutske preparacije su daljnji predmet izuma.
or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester prodrug form thereof. 
ili njegov tautomer ili njegova farmaceutski prihvatljiva sol ili njegov ester oblika prolijeka.
a decrease from baseline in 5-D Pruritus score of at least 25% or at least 30% through day 85 after administration of the first dose of the pharmaceutical composition comprising an anti-human IL-4R antibody or antigen-binding fragment thereof. 
(e) smanjenje rezultata ljestvice 5-D pruritus za najmanje 25 % ili najmanje 30 % u odnosu na osnovicu do 85. dana nakon primjene prve doze farmaceutskog pripravka koji sadrži antitijelo protiv humanog IL-4R ili njegov fragment koji se vezuje za antigen.
In certain embodiments, V is substituted with C1-C6 alkyl. Examples of heteroaryl groups include 5-6 membered rings having 1-2 atoms independently selected from N, S and O (provided the ring does not contain an O—O bond). 
(ili) S-V,-heteroaril gdje n je 1, V je Ci-C4 alkilen po izboru supstituiran s C;-Cg alkil, i heteroaril je 5-6-eročlani prsten s 1-2 atoma nezavisno izabrana između N, S i O;
Figure 9 depicts serum cholesterol levels in rats following treatment with 42-0-(D-fructosylcarbonyl)rapamycin and rapamycin. 
Slika 9 prikazuje serumske razine kolesterola u štakora nakon tretmana 42-O-(D-fruktozilkarbonil)rapamicinom i rapamicinom.
the playing surface (11) of the foundation body (10) looking from the interior of the foundation body (10) has an at least partially convex top surface (15), 
igraću površinu (11) osnovnog tijela (10) koja, gledano iz unutrašnjosti osnovnog tijela (10), ima u najmanju ruku djelomično udubljenu gornju površinu (15), -
wherein R1, R2 and R6 are as defined in claim 1; and wherein the chiral amine of formula (V) is of the formula (Vb) 
(lb) pri čemu su R1, R2 1 R6 kao što su definirani u zahtjevu 3; 1 kiralni amin formule (V) ima formulu (Vb):
The mouse of claim 15, wherein the mouse further comprises at an endogenous B2 microglobulin locus a nucleotide sequence encoding a human or humanized B2 microglobulin polypeptide. 
Miš prema zahtjevu 8 ili 12, naznačen time, da miš nadalje na endogenom B2-mikroglobulin-lokusu, obuhvaća nukleotidnu sekvencu koja kodira humani ili humanizirani B2-mikroglobulin-polipeptid.
These measurements indicate that at 300°C neat RME has evaporated completely from the metal surface. 
Ova mjerenja pokazuju da je pri 300"C čisti RME postupno ispario s površine metala.
The AAV vector of any one of claims 1 to 11, wherein the gene encodes the SMN protein and the said subject suffers from spinal muscular atrophy (SMA) disorder. 
AAV vektor iz patentnog zahtjeva 8, pri čemu gen kodira SMN protein i poremećaj je spinalna mišićna atrofija (SMA).
wherein the double-stranded cleavage is made by expressing a first fusion protein in the cell, the first fusion protein comprising a first zinc finger binding domain and a first cleavage half-domain, wherein the first zinc finger binding domain has been engineered to bind to a first target site in or near a Zp15 locus in the genome of the plant cell; and 
ekspresija prvog fuzijskog proteina u stanici, gdje prvi fuzijski protein obuhvaća prvu domenu vezanja cinkovih prstiju i prvu poludomenu cijepanja, dok se izvodi inženjering prve domene vezanja cinkovih prstiju, u svrhu vezanja prvog ciljanog mjesta u samom Zp15-lokusu ili u njegovoj blizini u genomu biljne stanice; i
to 99 wt % of a refractory, ceramic and/or construction raw material,wherein said raw material has an average grain size of from 0.1 to 60 µm; and optionally 
,1 do 99 wt % refraktorne, keramičke i/ili konstrukcijske sirovine, pri čemu spomenuta sirovina ima prosječnu veličinu zrna od 0,1 do 60 µm; i izborno
In a particularly preferred embodiment the entire present composition is derived from caramel, so that it can be labelled as “caramel”, “caramel colour”, “caramel isolate”, “caramel extract” or the like. 
U naročito poželjnom ostvarenju, cijeli sadašnji pripravak je dobiven od karamele, tako da se može označiti na deklaraciji kao "karamela", "boja od karamele", "izolat karamele", "ekstrakt karamele" ili slično.
The monoclonal antibody or antigen binding fragment thereof of claim 1 which binds to at least four CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, CCL14/HCC-1, and CCL18/PARC, and which does not bind to CCL2/MCP-1. 
23/24/25/28/29/30, ili koji se natječe za vezanje na najmanje četiri CC kemokina odabranih iz skupine koja se sastoji od CCL3/MIP-1a, CCL4/MIP-18, CCLS5/RANTES, CCLA/HCC-1, i CCLI8/PARC, s antitijelom ili fragmentom koji veže antigen koji sadrži kombinaciju CDR slijedova teškog i lakog lanca SEQ ID NO:
A device (1) for safe data transmission to railway beacons, characterized by comprising a first and a second circuit section (1a, 1b) independent of and galvanically separate from each other, and each comprising: 
Naprava (1) za siguran prijenos podataka prema željezničkim balizama, naznačena time, da sadrži prvu i drugu sekciju komunikacijskih krugova (la, 1b) nezavisnu i galvanski odijeljenu jedna od druge, i svaka sadrži:
Reaction of sodium salt with acid such as HCl provides carboxylic acid of formula (6-5). 
(7-4); reakciju natrijeve soli (7-4) s kiselinom radi dobivanja karboksilne kiseline s formulom (7-5),
The pharmaceutical composition according to claim 14, wherein the neurodegenerative disease is Alzheimer-type dementia or Down's syndrome. 
Spoj za uporabu prema zahtjevu 13, naznačen time da neurodegenerativna bolest je demencija Alzheimerovog tipa ili Downov sindrom.